Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718 · RASolute 305 Phase 3Recruiting
- Lead sponsor
- Revolution Medicines, Inc. (Industry)
- Enrollment
- 670 (estimated)
- Start date
- 22 May 2026
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 22 Apr 2030
- Last update posted
- 13 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Zoldonrasib Drug
- Placebo Drug
- Oxaliplatin Drug
- Leucovorin (Calcium Folinate) Drug
- 5-Fluorouracil Drug
- Irinotecan Drug
- Gemcitabine (GEM) Drug
- Nab-paclitaxel Drug
Conditions and primary outcome
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
Primary outcome
Progression free survival (PFS) (Up to approximately 4 years); Overall survival (OS) (Up to approximately 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07621718.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07621718 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.